Discounted Cash Flow Rating

Sell

Return on Equity Rating

Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Sell

Analyst Rating

Sell

Adverum Biotechnologies, Inc. Common Stock (ADVM)

Biological Products, (no Disgnostic Substances)

https://www.adverum.com

Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.

100 CARDINAL WAY
REDWOOD CITY, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

07/31/2014

Market Cap

141,030,102

Shares Outstanding

101,030,000

Weighted SO

101,027,174

Total Employees

N/A

Upcoming Earnings

08/08/2024

Beta

1.0580

Last Div

0.0000

Range

6.38-29.7

Chg

0.2500

Avg Vol

375977

Mkt Cap

141030102

Exch

NASDAQ

Country

US

Phone

650 656 9323

DCF Diff

6.9159

DCF

-0.3359

Div Yield

0.0000

P/S

-39.1750

EV Multiple

-0.7736

P/FV

0.8414

Div Yield %

0.0000

P/E

-1.4157

PEG

-0.0558

Payout

0.0000

Current Ratio

7.9880

Quick Ratio

8.2980

Cash Ratio

5.6685

DSO

-705.9708

DIO

-568.4401

Op Cycle

-1274.4109

DPO

161.0703

CCC

-1435.4812

Gross Margin

2.2419

Op Margin

32.6967

Pretax Margin

28.0494

Net Margin

27.7394

Eff Tax Rate

0.0016

ROA

-0.3935

ROE

-0.7445

ROCE

-0.5088

NI/EBT

0.9889

EBT/EBIT

0.8579

EBIT/Rev

32.6967

Debt Ratio

0.2911

D/E

0.4397

LT Debt/Cap

0.2737

Total Debt/Cap

0.3054

Int Coverage

-98.0900

CF/Debt

-1.1965

Equity Multi

1.5105

Rec Turnover

-0.5170

Pay Turnover

2.2661

Inv Turnover

-0.6421

FA Turnover

-0.0560

Asset Turnover

-0.0142

OCF/Share

-4.2397

FCF/Share

-4.2777

Cash/Share

8.3362

OCF/Sales

24.5572

FCF/OCF

1.0090

CF Coverage

-1.1965

ST Coverage

-8.3591

CapEx Coverage

-111.4830

Div&CapEx Cov

-111.4830

P/BV

0.8414

P/B

0.8414

P/S

-39.1750

P/E

-1.4157

P/FCF

-1.5811

P/OCF

-1.5992

P/CF

-1.5992

PEG

-0.0558

P/S

-39.1750

EV Multiple

-0.7736

P/FV

0.8414

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Nov 04, 17:54 Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023 GlobeNewswire Inc. Nov 04, 17:54 Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023 GlobeNewswire Inc. Nov 04, 17:54 Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023 GlobeNewswire Inc. Nov 04, 17:54 Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023 GlobeNewswire Inc. Nov 04, 17:54 Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023 GlobeNewswire Inc. Nov 04, 17:54 Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023 GlobeNewswire Inc. Nov 04, 17:54 Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023 GlobeNewswire Inc. Nov 04, 17:54 Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023 GlobeNewswire Inc. Nov 04, 17:54 Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023 GlobeNewswire Inc. Nov 04, 17:54 Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023 GlobeNewswire Inc. Nov 04, 17:54 Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023 GlobeNewswire Inc. Nov 04, 17:54 Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023 GlobeNewswire Inc. Nov 04, 17:54 Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023 GlobeNewswire Inc. Nov 04, 17:54 Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023

Revenue Product Segmentation